通过PRMT3介导的氨酸甲基化稳定PCSK9,促进大动脉的化
Xi Zhang1,2,3,4, Yanglin Hao1, Dong Han5
1Department of Cardiovascular Surgery, Huazhong University of Science and Technology, Wuhan, China. (X.Z., Y.H., X.S., W.Y., S.W., X.L., R.L., K.Z., Y. Liu, Z.Z., Z.T., Y. Li, Y.W., J.X., J.W.).
Circulation
|March 9, 2026
概括
蛋白质氨酸甲基转移酶3 (PRMT3) 通过稳定PCSK9.9驱动动脉疾病. 抑制或降解PRMT3会减少大动脉的化,提供潜在的治疗点.
科学领域:
- 心血管生物学 心血管生物学
- 疾病的分子机制.
- 生物化学 生化学
背景情况:
- 大动脉的化是性大动脉病 (CAVD) 的一个关键特征,增加了叶片的硬度.
- 驱动CAVD的精确分子和细胞机制仍然不完全理解.
- 蛋白质氨酸甲基转移酶3 (PRMT3) 正在研究其在膜化中的作用.
研究的目的:
- 调查PRMT3在膜化和CAVD的发病和进展中的作用.
- 阐明PRMT3影响膜化的分子机制.
主要方法:
- 人类大动脉叶片和膜间歇细胞 (VIC) 分析了PRMT3的表达.
- 在高胆固醇饮食中的ApoE缺乏的小鼠和Prmt3的哈普洛缺陷被用来研究体内化.
- 在体内评估了PRMT3的药理抑制 (SGC707) 和降解 (PROTAC).
- 生物化学分析,包括质谱和共免疫沉,用于确定PRMT3的作用机制.
主要成果:
- 在状大动脉中,PRMT3的表达显著上调,由RUNX2-介导的基因素乙化促进.
- 在小鼠中,Prmt3的哈普隆缺陷改善了大动脉的化,改善了心声学参数,并减少了骨质生殖标志物.
- 药理上抑制和降解PRMT3在体内表现出抗性作用.
- 通过其酶活性,PRMT3促进人体VIC的骨质分化,特别是通过在R582.2处甲基化PCSK9.
- 这种甲基化延长了PCSK9的半衰期,通过防止CHIP介导的全方位化和降解,从而加快了门化.
结论:
- 通过PCSK9稳定,PRMT3在促进大动脉结石化方面发挥着关键作用.
- 通过PRMT3介导的PCSK9的氨酸甲基化代表了CAVD中一种新的翻译后调节机制.
- 向PRMT3提供了一种潜在的治疗策略,通过破坏膜间歇细胞中的脂质-骨质生成合来管理CAVD.
更多相关视频
相关概念视频
Allosteric Proteins-ATCase
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...
Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Cholesterol: Significance and Regulation
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Considering cholesterol and...
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...


